NOVAVAX INC Total Contract Liability
NOVAVAX INC (NVAX) had Total Contract Liability of $443.33 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability $443.33M.
- 2026-03-31: Contract with Customer, Liability $448.05M.
- 2025-12-31: Contract with Customer, Liability $499.00M.
- 2025-09-30: Contract with Customer, Liability $501.36M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2026-06-30 | $443.33M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $448.05M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $499.00M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $501.36M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $513.03M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $517.89M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $1.12B 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $1.13B 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.20B 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $1.08B 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $863.52M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $801.03M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $907.41M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $689.83M 10-Q · filed 2024-05-10 | |
| 2022-12-31 | $549.55M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $1.44B 10-Q · filed 2023-11-09 | $202.50M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.52B 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $1.54B 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $1.60B 10-K · filed 2024-02-28 | |
| 2020-12-31 | $273.23M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |